Filing Details

Accession Number:
0000899243-21-031362
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-03 18:41:31
Reporting Period:
2020-03-24
Accepted Time:
2021-08-03 18:41:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492674 T2 Biosystems Inc. TTOO () NY
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
769993 Goldman Sachs & Co. Llc 200 West Street
New York NY 10282
No No Yes No
886982 Goldman Sachs Group Inc 200 West Street
New York NY 10282
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-03-24 500 $0.38 4,196,956 No 4 P Indirect See Footnotes
Common Stock Disposition 2020-03-24 500 $0.38 4,196,456 No 4 S Indirect See Footnotes
Common Stock Acquisiton 2020-03-25 600 $0.93 4,197,056 No 4 P Indirect See Footnotes
Common Stock Disposition 2020-03-25 600 $0.93 4,196,456 No 4 S Indirect See Footnotes
Common Stock Acquisiton 2020-04-09 1,000 $0.49 4,197,456 No 4 P Indirect See Footnotes
Common Stock Disposition 2020-04-09 1,000 $0.49 4,196,456 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-06 2,655 $0.52 4,193,801 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-06 1,000 $0.52 4,192,801 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-06 1,000 $0.53 4,191,801 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-06 500 $0.53 4,191,301 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-06 50 $0.53 4,191,251 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-06 500 $0.53 4,190,751 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-06 100 $0.53 4,190,651 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-06 6,256 $0.54 4,184,395 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-06 100 $0.55 4,184,295 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-06 939 $0.55 4,183,356 No 4 S Indirect See Footnotes
Common Stock Acquisiton 2020-05-06 26,200 $0.55 4,209,556 No 4 P Indirect See Footnotes
Common Stock Disposition 2020-05-06 10,100 $0.57 4,199,456 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-06 2,000 $0.57 4,197,456 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-06 1,000 $0.57 4,196,456 No 4 S Indirect See Footnotes
Common Stock Acquisiton 2020-05-12 2,500 $0.55 4,198,956 No 4 P Indirect See Footnotes
Common Stock Disposition 2020-05-12 2,500 $0.55 4,196,456 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-19 200 $0.83 4,196,256 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-19 3,235 $0.83 4,193,021 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-19 2,031 $0.83 4,190,990 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-19 2,031 $0.83 4,188,959 No 4 S Indirect See Footnotes
Common Stock Acquisiton 2020-05-19 10,328 $0.83 4,199,287 No 4 P Indirect See Footnotes
Common Stock Disposition 2020-05-19 800 $0.83 4,198,487 No 4 S Indirect See Footnotes
Common Stock Disposition 2020-05-19 2,031 $0.83 4,196,456 No 4 S Indirect See Footnotes
Common Stock Acquisiton 2020-05-20 5,126 $0.80 4,201,582 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 P Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 P Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 P Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 P Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 P Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 P Indirect See Footnotes
Footnotes
  1. These transactions in the common stock (the "Common Stock") of T2 Biosystems, Inc. (the "Issuer") have not previously been reported on Form 4 and were effected by Goldman Sachs & Co. LLC ("Goldman Sachs") acting as agent on behalf of certain international affiliates that had entered into riskless principal trades in connection with client trade facilitation in the ordinary course of their business.
  2. Without conceding riskless principal trades in connection with client trade facilitation in the ordinary course of business can result in liability under Section 16(b) of the Securities Exchange Act of 1934 (the "Exchange Act"), the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.
  3. This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group") and Goldman Sachs (together, with GS Group, the "Reporting Persons"). Goldman Sachs is a subsidiary of GS Group.
  4. GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of Common Stock of the Issuer by reason of the direct beneficial ownership of Common Stock by certain investment entities (the "GS Funds") because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs beneficially owns directly and GS Group may be deemed to beneficially own indirectly 29,216 shares of common stock.
  5. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.